Saturday 31 October 2026 Export MRNA’s income statement to Excel — free account

Moderna, Inc.

MRNA Healthcare Biotechnology

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.

Revenue: +2.11%
EPS: +7.51%
Free cash flow: +38.9%
Total debt: +1,765.6%

Quarter to June 2026, against a year earlier

221.72 1.04 −0.47%

Follow MRNA

Alert me

Market cap: $88.9B
P/E: 0.0×
Fwd P/E: −26.1×
Dividend yield: —
F-score: 3/9
Altman Z: 2.46
Beneish M: −3.52
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Filings

Moderna, Inc. (MRNA) revenue by segment, product and region

	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024	Q4 FY2023	Q3 FY2023	Q2 FY2023	Q1 FY2023
Collaboration Arrangement	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Collaborative Arrangement With Affiliate	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
COVID	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Stand-ready manufacturing revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Grant revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Collaboration Arrangement, Including Arrangements With Affiliate	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Licensing and royalty revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
RSV	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Net product sales	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Moderna, Inc. (MRNA) revenue by segment, product and region

Stockrow Weekly